Treatment of dural sinus thrombosis by urokinase infusion

AJNR Am J Neuroradiol. 1994 May;15(5):801-7.

Abstract

Purpose: To gain a preliminary understanding of the role of thrombolytic therapy for the thrombosed dural sinus, we retrospectively reviewed our initial experience.

Methods: Seven patients, ages 25 to 71, who presented with symptomatic dural sinus thrombosis and who failed a trial of medical therapy were treated with direct infusion of urokinase into the thrombosed sinus. Patients received urokinase doses ranging from 20,000 to 150,000 U/h with a mean infusion time of 163 hours (range 88 to 244 hours).

Results: Patency of the affected dural sinus was achieved with antegrade flow in all patients. Six patients either improved neurologically over their prethrombolysis state or were healthy after thrombolysis; one of them required angioplasty. The other patient improved after surgical repair of a residual dural arteriovenous fistula. The only complications were an infected femoral access site which resolved after treatment with antibiotics and hematuria which cleared after discontinuation of anticoagulation.

Conclusions: Thrombolysis of the thrombosed dural sinus shows promise as a safe and efficacious treatment. The results of this study should provide the impetus for further research.

MeSH terms

  • Adult
  • Aged
  • Cerebral Angiography
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Dura Mater / blood supply*
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neurologic Examination / drug effects
  • Sinus Thrombosis, Intracranial / diagnostic imaging
  • Sinus Thrombosis, Intracranial / drug therapy*
  • Sinus Thrombosis, Intracranial / etiology
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Urokinase-Type Plasminogen Activator / adverse effects

Substances

  • Urokinase-Type Plasminogen Activator